Benchmarking allowed us to: (1) determine whether viral infections were more predominant in CD30 patients due to increased respiratory pathogen testing during the SARS-CoV-2 pandemic or were more specific to CD30 CAR-T recipients relative to concurrent CD19 CAR-T recipients, and (2) provided a comparator group using the same methodology and definitions (prior studies are with CD19 CAR-T recipients and both microbiologically and clinically confirmed infections). This evidence concerns the gene TNFRSF8 and viral infectious disease.